Obstetrics & Gynecology Email Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 1984;63:630-634
© 1984 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by WORTSMAN, J.
Right arrow Articles by ALLEN, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by WORTSMAN, J.
Right arrow Articles by ALLEN, J. P.

Elevated Levels of Plasma ß-Endorphin and {gamma}3-Melanocyte Stimulating Hormone in the Polycystic Ovary Syndrome

JACOBO WORTSMAN, MD1, WILLIAM B. WEHRENBERG, PhD2, JAMES R. GAVIN, III, MD, PhD3 and JOHN P. ALLEN, MD4

1From the Department of Medicine, Southern Illinois University School of Medicine, Springfield, Illinois
2From the Laboratories for Neuroendocrinology, The Salk Institute, La Jolla, California
3From the Department Medicine, Washington University School of Medicine, St. Louis, Missouri
4From the Department of Neurosciences, Peoria School of Medicine, University of Illinois, Peoria, Illinois

Abstract

The authors have suggested that dysfunction of a central structure (above the pituitary level) is the primary etiologic factor responsible for the production of the polycystic ovary syndrome. To investigate further the functional integrity of the hypothalamic pituitary axis, plasma levels of /ß-endorphin, {gamma}3-melanocyte stimulating hormone, and {gamma}1-melanocyte stimulating hormone-like immunoreactivity were measured in six patients with polycystic ovary syndrome, and in ten women with normal ovarian function. The limit of sensitivity for the radioimmunoassays was 20 pg/mL. Plasma ß3-endorphin was significantly higher in polycystic ovary syndrome than in control subjects: (mean ± SE) 60 ± 10 versus 30 ± 4 pg/mL, respectively (P<.05). {gamma}3-Melanocyte stimulating hormone was detectable in four of six patients with polycystic ovary syndrome (mean for the whole group: 45 ± 15 pg/mL); it was undetectable in all the control subjects. Control of plasma ß-endorphin and {gamma}3-melanocyte stimulating hormone secretion in PCO was evaluated with metyrapone and dexamethasone. Overnight administration of metyrapone to polycystic ovary syndrome patients resulted in rises of ß-endorphin and {gamma}3-melanocyte stimulating hormone. Dexamethasone suppressed only partially (to basal concentrations) ß-endorphin and {gamma}3-melanocyte stimulating hormone levels. Plasma adrenocorticotropic hormone concentrations were within the normal range and displayed the expected changes in response to metyrapone and dexamethasone. The present report presents an additional central (hypothalamic-pituitary) abnormality in patients with the polycystic ovary syndrome.




This article has been cited by other articles:


Home page
 EndocrinologyHome page
F. R. Kandeel and R. S. Swerdloff
The Interaction between {beta}-Endorphin and Gonadal Steroids in Regulation of Luteinizing Hormone (LH) Secretion and Sex Steroid Regulation of LH and Proopiomelanocortin Peptide Secretion by Individual Pituitary Cells
Endocrinology, February 1, 1997; 138(2): 649 - 656.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Diagnostic Medical SonographyHome page
K. J. Garten and R. P. Pulliam
Prenatal Diagnosis of Lethal Shor-limbed Dwartism
Journal of Diagnostic Medical Sonography, January 1, 1985; 1(1): 7 - 13.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1984 by the American College of Obstetricians and Gynecologists.